Investigational Studies

London (ots/PRNewswire) – – Pharmazeutische Cannabidiol-Formulierung reduziert signifikant die Hufigkeit von Krampfanfllen bei Kindern, die schlecht auf Behandlung mit multiplen Antiepileptika ansprechen – – Erste ordnungsgem kontrollierte klinische Studie zu Cannabidiol beim Dravet-Syndrom, einer seltenen, schweren Form der Epilepsie, fr die keine von der FDA-zugelassene Therapie vorliegt – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW”, “das […]

– Pharmaceutical formulation of cannabidiol significantly reduced convulsive seizure frequency in children on multiple anti-epileptic drugs with poor seizure control – – First well-controlled clinical study of cannabidiol in Dravet syndrome, a rare, severe type of epilepsy with no FDA-approved treatments – LONDON, May 24, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or […]

Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a report issued on Thursday, April 20th. The brokerage issued a buy rating and a $135.00 price objective on the biopharmaceutical company’s stock. “Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are […]

– Dr. Volker Knappertz appointed Chief Medical Officer –– Professor Ben Whalley to join as Head of Discovery Research – LONDON, May 15, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced […]

Last year was a doozy for biotech, but it was spectacular for GW Pharmaceuticals. Its streak continues with more special treatment. GW Pharmaceuticals, which is developing epilepsy treatments from marijuana, is making a name for itself not just as “that company” turning a recreational drug into medical ones; the company was also one of 2016’s surprise successes — its […]

– Dr. Volker Knappertz appointed Chief Medical Officer –– Professor Ben Whalley to join as Head of Discovery Research – LONDON, May 15, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced […]

– Epidiolex® NDA submission expected mid-year –– New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology –– Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics […]

– Dr. Volker Knappertz appointed Chief Medical Officer –– Professor Ben Whalley to join as Head of Discovery Research – LONDON, May 15, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced […]

Receive News Stock Ratings for GW Pharmaceuticals PLC- Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GW Pharmaceuticals PLC- and related stocks with our FREE daily email newsletter. … read more at: https://www.thecerbatgem.com/2017/05/11/gw-pharmaceuticals-plc-gwph-receives-new-coverage-from-analysts-at-maxim-group-updated-updated.html

– Epidiolex® NDA submission expected mid-year –– New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology –– Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics […]

– Epidiolex® NDA submission expected mid-year –– New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology –– Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics […]

– Epidiolex® NDA submission expected mid-year –– New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology –– Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics […]